Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Who May Qualify: The main inclusion criteria include but are not limited to the following: - Has a confirmed diagnosis of ulcerative colitis (UC) - Has moderate to severely active UC as defined by the 3-component Modified Mayo clinic score - Has an inadequate response, loss of response, or intolerance/medical contraindication to at least one of the following therapies: oral aminosalicylates, corticosteroids, immunosuppressants, anti-tumor necrosis factor biologic, anti-interleukin 12/23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators Who Should NOT Join This Trial: The main exclusion criteria include but are not limited to the following: - Has diagnosis of Crohn's disease or indeterminate colitis - Has had extensive colonic resection - Has colostomy or ileostomy - Has uncontrolled primary sclerosing cholangitis Always talk to your doctor about whether this trial is right for you.